BACKGROUND
One of the earliest diagnostic signs of hepatorenal syndrome in patients suffering from liver
cirrhosis is an increase in the renal vascular resistive index (RI). In this study, the impact of
propranolol on decreasing this index and to postpone the probability of hepatorenal syndrome
has been investigated.
METHODS
In the current research, 30 patients with liver cirrhosis with different age and sexes have been
enrolled. Demographic data and complete medical history have been collected using a specific
questionnaire. At first, renal artery Doppler ultrasonography was performed to determine the RI.
The patients were then treated with propranolol, and under supervision, the dose of the drug was
increased gradually every 3 to 5 days to reach the target of 25% decrease in resting heart rate. One
month after reaching the target dose of the medicine, Doppler ultrasonography was repeated for
the patients and the second RI was compared with the pretreatment ones.
RESULTS
According to our results after treatment with propranolol, a significant decrease of RI was
observed (
p
< 0.01). However, there was no significant difference in the glomerular filtration rate
(GFR) before and after treatment with propranolol (
p
= 0.290). In our study, we found that administering
propranolol was associated with significant changes in RI and GFR between the patients
with compensated and decompensated cirrhosis (mean change: -0.005 ± 0.017 vs. -0.058 ± 0.045;
p
< 0.01 for RI and -4.226 ± 17.440 vs. 13.486 ± 12.047;
p
< 0.01 for GFR in patients with compensated
and decompensated cirrhosis, respectively).
CONCLUSION
Propranolol reduces renal vascular RI in patients with cirrhosis. The response rates in the patients
with decompensating cirrhosis were significantly higher than the patients with compensating cirrhosis